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Abstract
Background: Bacterial artificial chromosomes (BACs) have been used extensively for sequencing
the human and mouse genomes and are thus readily available for most genes. The large size of
BACs means that they can generally carry intact genes with all the long range controlling elements
that drive full levels of tissue-specific expression. For gene expression studies and gene therapy
applications it is useful to be able to retrofit the BACs with selectable genes such as G418
resistance, reporter genes such as luciferase, and oriP/EBNA-1 from Epstein Barr virus which allows
long term episomal maintenance in mammalian cells.
Results:  We describe a series of retrofitting plasmids and a protocol for in vivo loxP/Cre
recombination. The vector pRetroNeo carries a G418 resistance cassette, pRetroNeoLuc carries
G418 resistance and a luciferase expression cassette, pRetroNeoLucOE carries G418 resistance,
luciferase and an oriP/EBNA-1 cassette and pRetroNeoOE carries G418 resistance and oriP/EBNA-1.
These vectors can be efficiently retrofitted onto BACs without rearrangement of the BAC clone.
The luciferase cassette is expressed efficiently from the retrofitting plasmids and from retrofitted
BACs after transient transfection of B16F10 cells in tissue culture and after electroporation into
muscles of BALB/c mice in vivo. We also show that a BAC carrying GFP, oriP and EBNA-1 can be
transfected into B16F10 cells with Lipofectamine 2000 and can be rescued intact after 5 weeks.
Conclusion:  The pRetro vectors allow efficient retrofitting of BACs with G418 resistance,
luciferase and/or oriP/EBNA-1 using in vivo expression of Cre. The luciferase reporter gene is
expressed after transient transfection of retrofitted BACs into cells in tissue culture and after
electroporation into mouse muscle in vivo. OriP/EBNA-1 allows stable maintenance of a 150-kb BAC
without rearrangement for at least 5 weeks.
Background
BACs and PACs have proven very useful vectors for clon-
ing fragments of mammalian DNA up to about 300 kb in
size. They have been used extensively for the sequencing
of the mouse and human genomes and the clones from
these sequencing projects are available making almost the
entire genomes available in ready sequenced clones.
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For gene delivery and expression in tissue culture, or for
gene therapy, the large inserts of the BACs are very useful
as they generally contain all the long range controlling el-
ements needed for full levels and tissue specific expression
of genes. In addition the inserts of the BACs can be subtly
modified to include reporter genes or point mutations us-
ing homologous recombination in E. coli mediated by
RecA [1–3], the RecET system [4–7] or the Red system
(Redα/Redβ or exo/bet)[8,9].
For tissue culture and gene therapy applications it is often
useful to have mammalian selectable markers, reporter
genes and other elements on the vector region of the
BACs. It is possible to subclone the entire insert of the
BAC into a modified BAC vector [10,11] however, this in-
volves cloning >100-kb fragments which is technically
tricky. One can use homologous recombination mediated
by RecA, RecET, or Red as described in the papers listed
above. Alternatively one can use recombination of loxP
sites mediated by Cre protein. We have chosen to use loxP/
Cre recombination as all BACs and PACs carry convenient
loxP sites and Cre only recombines loxP sites which should
reduce unwanted rearrangements in the BAC insert. How-
ever, prior to insertion of DNA onto a BAC at a loxP site, it
is necessary to remove or inactivate any high-copy origins
from the retrofitting DNA as such an origin would make
the BAC multicopy. Various methods for retrofitting new
DNA at the loxP site using Cre recombinase have been de-
veloped. Kim et al, 1998, described a method in which the
retrofitting plasmid is cut to remove the high-copy origin
of replication and religated into a circle prior to in vitro re-
combination with purified BAC DNA using Cre protein
followed by transfection into E. coli [12,13]. An improve-
ment is to use a retrofitting plasmid which has the gamma
origin of replication from the R6K plasmid which only op-
erates in an E. coli host which expresses the π protein
(product of the pir gene) so that once the plasmid is retro-
fitted onto the BAC the origin is not functional in the
DH10B E. coli host [14]. The in vitro recombination with
Cre tends to be rather inefficient and this can be overcome
by expressing the Cre protein in the E. coli carrying the
BAC so that recombination occurs in vivo. In one system,
the Cre protein is expressed from the retrofitting plasmid
itself in vivo. The Cre-expressing gene is however interrupt-
ed by the loxP site so that once recombination has oc-
curred, no further Cre is expressed [15]. Alternatively the
Cre can be expressed from a separate plasmid that is co-
transfected with the retrofitting plasmid, and then lost
once retrofitting has occurred. This has been used to intro-
duce an origin-less circle of DNA onto a BAC [16] or plas-
mids with the gamma origin onto BACs [17].
Epstein Barr virus is maintained as a ~172 kb episome in
a small proportion of B cells in most of the human popu-
lation. The only viral elements needed for the episomal
maintenance of plasmids in human cells is the latent ori-
gin of plasmid replication, oriP, and the viral protein
EBNA-1. Plasmids carrying an oriP/EBNA-1 cassette can be
maintained in human cells under selection for long peri-
ods of time. They are present at about 1–100 copies per
cell and segregate by non-covalent attachment to the host
chromosomes. When selection is dropped the episomes
are lost at about 1–5% per cell division. There is much in-
terest in using oriP/EBNA-1-containing vectors for gene
therapy [18]. The presence of oriP/EBNA-1 on gene expres-
sion vectors with reporter genes or mini-genes has been
found to confer higher levels of expression and more per-
sistent expression both in vitro and in vivo [19–22]. An
oriP/EBNA-1 cassette is able to stabilize episomes up to
660 kb in size when these are shuttled from yeast by fu-
sion with yeast spheroplasts [23,24]. Finally it has been
shown that therapeutically important genes can be ex-
pressed from the intact loci carried on large oriP/EBNA1-
containing vectors, including β-globin [25], CFTR
[24]HPRT [17,26] and α1-antitrypsin [27].
Here we describe four new retrofitting vectors which allow
addition of G418 resistance, luciferase expression and/or
oriP/EBNA-1 to BACs, and a simple protocol based on
those of Mejia and Larin, 2000 and Wade-Martins et al.,
2001 for in vivo recombination with Cre. The luciferase
gene on retrofitted BACs is expressed after transient trans-
fection of cells in tissue culture and after electroporation
of mouse muscle in vivo. A BAC carrying oriP/EBNA-1 was
used to make stable cell lines which contained unrear-
ranged BAC DNA after 5 weeks.
Results
New vectors
A series of new vectors for retrofitting BACs was construct-
ed (Fig. 1a). The vectors carry bacterial elements including
the gamma origin of replication which only functions in
bacteria expressing the π protein, a loxP site, and a spectin-
omycin resistance gene (SpR). In addition, they carry vari-
ous mammalian elements. pRetroNeo carries a G418
resistance cassette (NeoR). pRetroNeoLuc carries G418 re-
sistance and a luciferase expression cassette (Luc). pRetro-
NeoLucOE carries G418 resistance, luciferase and an oriP/
EBNA-1 cassette (OE). pRetroNeoOE carries G418 resist-
ance and oriP/EBNA-1.
In vivo retrofitting
In order to retrofit the various pRetro plasmids onto a
BAC, the plasmid is co-transfected into the BAC-contain-
ing bacteria along with a Cre-expression plasmid
pJM2545 [16]. pJM2545 contains a lacZ-cre fusion gene so
that the Cre protein is expressed after IPTG induction. It
also has a temperature sensitive origin that is functional at
30°C. As presented in Figure 2a, in vivo retrofitting of a
BAC with the pRetro vectors occurs at 30°C and then theBMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/2
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bacteria are grown at 42°C so that pJM2545 is lost.
Growth on plates containing both chloramphenicol and
spectinomycin allows selection for the retrofitted BACs.
Figure 1b gives maps of the standard BAC vectors
pBeloBAC11 [28] and pBACe3.6 [29,30] before and after
retrofitting with pRetroNeo and pRetroNeoLucOE
respectively.
Three BACs were retrofitted in this work. BACLucA carries
70 kb of alphoid DNA and already carries a luciferase gene
on the BAC vector. This BAC was retrofitted with pRetro-
NeoOE to introduce both a G418-resistance gene andoriP/
EBNA-1. NotI was used to determine whether retrofitting
had occurred correctly. The unmodified BACLucA has a
~10-kb vector fragment while BACLucARetroNeoOE has a
~20-kb fragment (Fig. 1c and 2b). With a control plasmid
the transfection efficiency was about 2000 colonies (2 ×
104 per µg) and about 30 colonies were obtained on the
retrofitting plates. 15/15 bacterial clones that were ana-
lysed showed the correct pattern of retrofitting. The insert
of the BAC with 70 kb of alphoid DNA was unrearranged
in all 15 BAC colonies analysed. In two of the 15 colonies,
Figure 1
Maps of the retrofitting vectors, BACs and the retrofitted BACs a) pRetro vectors; pRetroNeo, pRetroNeoLuc, 
pRetroNeoLucOE and pRetroNeoOE. Selected restriction sites are indicated. b) Retrofitting of standard BACs; pBeloBAC11, 
pBeloBAC11 retrofitted with pRetroNeo (pBeloBACRetroNeo), pBACe3.6, and pBACe3.6 retrofitted with pRetroNeoLucOE 
(pBACe3.6RetroNeoLucOE). NotI sites are indicated. c) Retrofitting of specific BACs; BACLucA, BACLucARetroNeoOE, 
BACGFPNeoOE, and BACGFPNeoOERetroNeoLuc. NotI sites are indicated. The following elements are labelled; spectinomy-
cin resistance gene (SpR), gamma origin from the R6K plasmid (R6K ori), loxP site (LoxP), G418 resistance cassette (NeoR), 
luciferase expression cassette (Luc), oriP from Epstein Barr virus (OriP), EBNA-1 gene from Epstein Barr virus (EBNA-1), chlo-
ramphenicol resistance gene (CmR), F1 origin from the F factor (F1 ori), SacBII gene (SacBII), lacZ gene (LacZ) and EGFP 
expression cassette (eGFP).
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Insert Insert
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the bacteria contained both retrofitted and unretrofitted
BAC DNA (data not shown).
The second BAC, BACGFPNeoOE, carries a 130-kb ran-
dom human DNA insert and has a GFP expression cas-
sette, G418 resistance and oriP/EBNA-1  already on the
BAC vector. It was retrofitted with pRetroNeoLuc to give
BACGFPNeoOERetroNeoLuc. In this case the original 18-
kb vector fragment is changed to two fragments of 22 and
3 kb (Fig. 1c and 2b). On control plates about 1000 colo-
nies (104 per µg) were obtained while there were seven on
the retrofitting plates. Seven colonies were analysed and 7
were correctly retrofitted but 1 had a rearrangement in the
insert (data not shown).
Thirdly, BAC 4B19 which contains about 150 kb of al-
phoid DNA in the BACe3.6 vector was retrofitted with
pNELγ. This vector retrofits G418 resistance and EGFP ex-
pression and carries a loxP site and the gamma origin [14].
The 8.7-kb vector fragment of BACe3.6 is replaced by frag-
ments of 6.8 kb, 4.1 kb, 3.4 kb and 2.6 kb (Fig. 2c). 50
colonies were obtained, 6 out of 6 analysed had been cor-
rectly retrofitted but 5 out of 6 had deletions (up to 40 kb)
in the alphoid DNA.
Expression of luciferase in vitro
In order to determine whether the luciferase gene on the
retrofitting vectors was functioning before and after retro-
fitting, transient transfections were carried out into the
Figure 2
In vivo retrofitting of BACs a) The pRetro plasmids are cotransfected with a Cre-expression plasmid, pJM2545, into the 
BAC-containing E. coli. PJM2545 carries a temperature sensitive origin of replication (reptc) kanamycin resistance (KmR) and an 
inducible cre gene (Cre). Recombination between the loxP sites (LoxP) results in the retrofitted BACs which carry both chlo-
ramphenicol and spectinomycin resistance (CmR and SpR). b) Pulsed-field gel showing retrofitted BACs. BAC DNA was 
digested with NotI and separated on a pulsed-field gel. Lane 1) BACLucA, 2) BACLucARetroNeoOE, 3) BACGFPNeoOE and 4) 
BACGFPNeoOERetroNeoLuc. M indicates the Low Range PFG Marker from Biolabs. Sizes of the markers are indicated on the 
right. c) Pulsed-field gel showing BAC 4B19 retrofitted with pNELγ. DNA from BAC 4B19 (BAC) and the BAC retrofitted with 
pNELγ (BACNEL) was digested with NotI and separated on a pulsed-field gel. L indicates the 1 Kb DNA Ladder from GibcoBRL 
and M indicates the Low Range PFG Marker from Biolabs. The sizes of the markers are indicated on the right.
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mouse cell line B16F10 using PEI22. Transfections were
carried out with 1 µg of the plasmids pCMV-LUC, pCIK-
Lux, pRetroNeoLuc, and pRetroNeoLucOE, and 3 µg of
the BACs BACLucA, BACLucARetroNeoOE and BACGFP-
NeoOERetroNeoLuc. Two separate experiments were car-
ried out with triplicate samples and the results are shown
in Figure 3. The retrofitting plasmids give almost identical
luciferase expression to the control pCMV-LUC and pCIK-
Lux plasmids. Expression of luciferase is approximately 25
fold lower when the BAC DNA is transfected. Three times
the mass of BAC DNA as plasmid DNA was delivered, but
the BACs are much larger (average 108 kb) than the plas-
mids (average 7.8 kb), so we were delivering approximate-
ly 1/5 the number of BAC as plasmid molecules.
Therefore, the lower number of molecules (5 fold less)
does not entirely account for the lower expression (25
fold less) from the BACs – we obtained an approximately
5 fold less efficient delivery of BAC DNA per molecule. In
addition, it is clear that in these transient experiments as-
sayed 24 hours after transfection, there is no difference be-
tween the corresponding constructs with or without oriP/
EBNA-1 (pRetroNeoLuc versus pRetroNeoLucOE and BA-
CLucA versus BACLucARetroNeoOE).
Intact delivery and maintenance of a BAC with oriP/
EBNA-1
To investigate delivery and maintenance of BACs carrying
oriP/EBNA-1  elements, stable cell lines were generated
with BACGFPNeoOE which carries oriP/EBNA-1 on the
vector. Purified BAC DNA was delivered to B16F10 cells
with Lipofectamine 2000 and six stable cell lines were se-
lected with G418. After 30 days of culture under selection
Figure 3
Transient transfection showing the luciferase expression measured at 24 hours Plasmid (1 µg) and BAC (3 µg) 
DNA as indicated below the bars was transfected into the cells with PEI22. Two separate experiments were carried out. Each 
experiment was done in triplicate and the error bars indicate the standard deviation.
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the percentage of GFP expressing cells was determined by
FACs analysis (Fig. 4a). Between 63 and 98% of the cells
in each cell line expressed GFP.
After 35 days in culture, high-molecular-weight DNA was
prepared from the six cell lines and electroporated into
bacteria which were then grown on chloramphenicol-con-
taining agar. DNA was extracted from 5 clones from each
of the six cell lines, digested with SalI and analysed on an
agarose gel (three are shown for each mammalian cell line
in Fig. 4b). In 5 of the cell lines (1, 3, 4, 5 and 6) the BAC
DNA extracted from the mammalian cells matched the in-
put BAC DNA in all 5 E. coli clones. One cell line, number
2, gave some E. coli clones with rearranged BACs; of 8
clones analysed from this cell line, 4 were rearranged, al-
ways in the insert rather than the vector region, while 4
were unrearranged. To further investigate the rescued BAC
DNA, a pulsed-field gel was used to fully resolve the BAC
fragments for 3 of the clones from cell line 4 (Fig. 4c). It is
clear that the SalI fragments of the rescued DNA exactly
match the input DNA. The BAC DNA has therefore been
Lipofected intact into the cells and maintained as epi-
somes for 37 days without rearrangement.
In vivo transfection
BAC DNA was also introduced into muscles in vivo by in-
jection followed by electroporation. BACLucA, BACLu-
cARetroOE and BACGFPNeoOERetroNeoLuc all gave
approximately the same amount of luciferase expression,
approximately 5 × 105 RLU, 24 hours after electropora-
tion. Muscles from untransfected mice gave the same as
background levels (about 50 RLU). The presence of oriP/
EBNA-1 on the BAC does not make a significant difference
to the level of expression at 24 hours (compare BACLucA
and BACLucARetroOE). The control plasmid pCMV-LUC
(5.9 kb) gave approximately 100 fold more luciferase ex-
pression than the BACs (average 108 kb). In this case the
same mass of plasmid and BAC were electroporated so ap-
proximately 18 times as many copies of plasmid were ap-
plied indicating that BAC transfer is approximately 5 fold
less efficient per copy.
Discussion
As all BACs carry a loxP site and do not carry the spectino-
mycin resistance gene these plasmids are of general use for
retrofitting. G418 resistance allows selection of stable
transformants in tissue culture, the luciferase expression
cassette allows efficient quantitation of gene expression in
tissue culture and in vivo while oriP/EBNA-1 allows stable
maintenance as episomes in tissue culture and possibly in
vivo.
The in vivo retrofitting protocol is very efficient giving tens
of colonies from a single electroporation. Almost all the
colonies that grow contain the correctly retrofitted BAC.
The only rearrangements observed were in the two larger
BACs. The 70-kb insert consisting of alphoid DNA did not
rearrange. The 130 kb of random human DNA rearranged
very rarely while the 150 kb of alphoid DNA usually rear-
ranged. Alphoid DNA consists of almost identical tandem
repeats so the ability to retrofit the BAC with 150 kb of al-
phoid DNA without rearrangement is a stringent test of
this system. The in vivo retrofitting works with both the
new pRetro vectors and with the previously described ret-
rofitting vectors pNELγ, which carries G418 resistance and
EGFP, and pNELγI which carries also an I-SceI site for lin-
earisation [14]. In addition, the modular nature of the
pRetro vectors allows other selectable markers or reporter
genes to be easily added.
Transfection of the retrofitting plasmids and retrofitted
BACs with PEI22 showed that the luciferase was efficiently
expressed. Expression from the BACs was only about 5
fold less per molecule than for the control plasmids indi-
cating that the BAC DNA up to 155-kb in size is being de-
livered only moderately less efficiently than small plasmid
DNA with PEI22.
Stable transfection of a 150-kb BAC carrying oriP/EBNA-1
was used as a stringent test of the ability to transfect such
large DNA intact into mammalian cells in tissue culture.
Rescue of episomal BAC DNA into E. coli is a quick and ef-
ficient way of determining whether the BAC DNA has
been delivered and maintained intact [31]. Delivery of the
155-kb BAC with Lipofectamine 2000 resulted in 5 out of
6 mammalian cell lines which carried only the intact BAC
after 35 days in culture while the 6th had some rearranged
and some intact BAC episomes. Other investigators have
described intact delivery of similarly sized oriP/EBNA1-
BACs. A 200-kb oriP/EBNA1-BAC was delivered with Lipo-
fectamine but the intactness of the DNA was not analysed
in detail and only pools of cell clones were analysed [25].
A 117-kb oriP/EBNA1-BAC was delivered by calcium
phosphate co-precipitation but only one cell line was de-
scribed so the frequency with which such large DNA was
delivered and maintained intact is not clear [31]. In a fur-
ther study, delivery of a 130-kb oriP/EBNA1-BAC with
lipofectin/integrin-binding peptide/DNA (LID) complex
resulted in only 2 cell lines out of many screened with the
intact BAC DNA [26]. In addition, a very effective viral
packaging and delivery system has been described for oriP/
EBNA1-BACs up to about 150 kb in size [17]. Thus,
Lipofectamine 2000 is the best of the non-viral delivery
systems which have been used to deliver oriP/EBNA1-
BACs intact.
In vivo delivery by injection of DNA into muscle followed
by electroporation with electric pulses of low field
strength and long duration has been used to efficiently de-
liver plasmid DNA. The level of expression from plasmidBMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/2
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Figure 4
Analysis of stable cell lines 0.5 µg of BACGFPNeoOE DNA was transfected into B16F10 cells with Lipofectamine 2000 and 
6 clones were expanded in G418 selection. a) The percentage of cells expressing GFP was determined by FACs analysis at 30 
days. B16F10 indicates untransfected cells. b) Analysis of DNA rescued from the 6 stable cell lines. DNA was extracted from 
the 6 cell lines and re-transfected into E. coli. DNA from 3 E. coli clones are shown for each B16F10 cell line as indicated above 
the lanes. Cell line number 2 gave rearranged BAC DNA in two E. coli clones, while the third is unrearranged. DNA was cut 
with SalI and resolved on a 0.3% SeaKem Gold agarose gel. Size marker M1 is the 1 kb DNA Ladder from Promega and M2 is 
the Lambda DNA-Mono Cut Mix from Biolabs. In between the two markers is the input BAC DNA cut with SalI. The sizes of 
the markers and BAC fragments are shown on the left and right of the gel respectively. c) Pulsed-field gel showing that the 
BAC DNA rescued from the cell lines is the same as the input DNA. The lanes carry; Low Range PFG marker (Biolabs)(M), 
input BACGFPNeoOE DNA cut with SalI (input), and DNA from three E. coli clones from cell line number 4 (4a, 4b and 4c) cut 
with SalI. The sizes of the markers and BAC fragments are indicated on the left and right of the gel respectively.
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DNA is generally 30–150 fold higher than with microin-
jection alone [32–36]. The expression obtained here with
BAC DNA was only about 5 fold lower per molecule than
with the plasmid DNA indicating that in vivo electropora-
tion into muscle is a very effective method for delivering
DNA up to at least 150 kb in size.
Conclusions
The pRetro vectors allow efficient retrofitting of BACs with
G418 resistance, luciferase and/or oriP/EBNA-1, by in vivo
loxP/Cre recombination. The retrofitted BAC DNA can be
efficiently delivered to cells in tissue culture and to mouse
muscles in vivo and the luciferase gene is well expressed.
The BAC DNA is transfected only about 5 fold less effi-
ciently than plasmid DNA using PEI22 in vitro or
electroporation into muscles in vivo. Lipofectamine 2000
allowed intact transfection of a 150-kb BAC into cells in
tissue culture and the BAC was maintained as an oriP/
EBNA-1 episome for 35 days without rearrangement of
the DNA. Retofitting of BACs with these vectors should fa-
cilitate long-term gene expression from BAC clones for
study of gene expression and for gene therapy
applications.
Figure 5
In vivo delivery and expression of luciferase Twenty µg each of plasmid pCMV-LUC and BACs BACLucA, BACLucARet-
roOE, and BACGFPNeoOERetroNeoLuc DNA was injected and electroporated into mouse muscle. Luciferase expression 
was assayed 24 hours after gene delivery. Background levels in un-treated mice is about 50 RLU.
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Methods
Plasmids and BACs
The 2.2-kb HindIII fragment carrying the spectinomycin
resistance gene from pWM5 [37] was cloned into the Hin-
dIII site of pBluescript II KS (Stratagene) to give pLP1S.
The 1.1-kb XhoI-SalI fragment from pMC1neo Poly A
(Stratagene) was cloned into the SalI site of pLP1S to give
pLP3S. The 3.3-kb XhoI-EcoRV fragment containing the
spectinomycin resistance and G418 resistance genes from
pLP3S was cloned to a 700-bp XhoI-PvuII fragment carry-
ing the gamma origin (R6K ori) and loxP site from pUni/
V5-His-TOPO (Invitrogen) to give pRetroNeo. The host
bacteria for pRetroNeo and all the other pRetro vectors
were PIR1 cells (Invitrogen).
A 3-kb BglII-NaeI (BglII end blunt ended with Kenow
+dNTPs) from pCIKLux [38] carrying a luciferase expres-
sion cassette was cloned into pRetroNeo cut with KpnI
(and the ends blunt ended with Klenow without dNTPs)
to give pRetroNeoLuc. The plasmid pCIKLux consists of
1.6 kb of luciferase ORF from pGL3 (Promega) cloned
into pCI (Promega) so that it is driven by the CMV pro-
moter and enhancer.
The 5.7-kb SalI-FspI fragment from pCEP4 (Invitrogen)
carrying the oriP/EBNA-1 cassette was cloned into SalI-
PvuII cut pSP73 Vector (Promega) to give pSP73OE. The
5.7-kb SalI-XhoI fragment from pSP73OE carrying oriP/
EBNA-1 was cloned into pRetroNeoLuc cut with SalI to
give pRetroNeoLucOE.
The 5.7-kb SalI-XhoI fragment from pSP73OE was also
cloned into SalI cut pRetroNeo to give pRetroNeoOE.
The control plasmids pCMV-LUC [39] and pCIKLux [38]
were also used in transfections.
BACLucA has a vector based on pBeloBAC 11 [28] but
with a luciferase expression casette (pLUCBAC) [40] and
then 70 kb of alphoid DNA from pPAC4-7c5 [41] cloned
into the vector. The vector of BACGFPNeoOE is also based
on pBeloBAC 11 but also has a GFP expression cassette,
G418 resistance and oriP/EBNA-1. The insert of BACGFP-
NeoOE is a random 130-kb human insert [40]. BAC 4B19
has a pBACe3.6 vector [30] and contains about 150 kb of
alphoid DNA.
In vivo retrofitting method
To make the BAC-containing bacteria electrocompetent,
99 ml of LB with 12.5 µg/ml chloramphenicol was inocu-
lated with 1 ml of saturated culture of the bacteria and
grown for about 3 hours at 37°C with shaking till an
OD600 of 0.6–0.8 was reached. The culture was cooled
down on ice for 30 min. Two lots of 50 ml were spun
down at 3,000 rpm (Sorval) for 15 mins at 4°C, rinsed
twice with 10 ml ice cold water, washed (with resuspen-
sion) with ice cold 10% glycerol and finally resuspended
in 250 µl (per 50 ml of bacterial culture) of ice cold 10%
glycerol. Then aliquots of 40 µl per 1.5 ml tube were snap
frozen with liquid nitrogen and stored at -70°C or used
directly.
100 ng of the retrofitting plasmid and 100 ng of pJM2545
[16] were electroporated into the bacteria using 1 mm cu-
vettes and a BioRad electroporator (Gene Pulser II) at 1.8
kV, 25 µF and 200 Ohm. 1 ml of LB with 0.5 mM IPTG
was added and incubated at 37°C for 1 hour with shak-
ing. The bacteria were spun down and plated in total on
an LB plate with 12.5 µg/ml chloramphenicol and 50 µg/
ml spectinomycin. The plates were incubated at 30°C for
75 minutes and then at 42°C overnight.
BAC DNA preparation
BAC DNA for transfection was prepared with Qiagen End-
oFree Plasmid Mega Kit (without using the QIAfilter
Cartridges supplied in this Kit). Cultures of BACs were
grown overnight at 37°C in 2.5 L of LB medium contain-
ing 12.5 µg/ml chloramphenicol. The bacteria were har-
vested in 500 ml aliquots by centrifugation for 20 min at
4°C and 6,000 × g in a Sorvall GS3-Rotor. The pellet was
resuspended in 200 ml ice-cold buffer P1. 200 ml buffer
P2 was then added and mixed gently but thoroughly by
inverting the tube 4–6 times. The mixture was incubated
at room temperature for 5 min. 200 ml ice-cold buffer P3
was added, mixed gently but thoroughly by inverting the
tube 4–6 times, and the mixture incubated for 30 min on
ice. The mixture was centrifuged at 20,000 × g for 30 min
at 4°C. The supernatant containing the BAC DNA was re-
moved and re-centrifuged at 20,000 × g for 15 min at 4°C.
The supernatant containing the BAC DNA was transferred
into a fresh bottle and 50 ml of buffer ER added, mixed
gently but thoroughly by inverting 10 times, and incubat-
ed on ice for 30 min. A QIAGEN-tip 2500 was equilibrat-
ed by adding 35 ml QBT buffer and allowing the column
to empty by gravity flow. The DNA solution was loaded
onto the QIAGEN-tip and allowed to enter the resin by
gravity flow. The QIAGEN-tip was washed with 4 × 50 ml
buffer QC. The DNA was eluted with 5 × 7 ml buffer QN
(preheated to 65°C). The DNA was precipitated by adding
24.5 ml isopropanol, followed by centrifugation at
15,000 × g for 30 min, 4°C. The supernatant was carefully
decanted and the DNA washed with 7 ml endotoxin-free
70% ethanol at room temperature. The tube was immedi-
ately centrifuged at 15,000 × g for 10 min, 4°C and the su-
pernatant carefully decanted without disturbing the
pellet. The pellet was air dried for approximately 10–20
min and the DNA re-dissolved in 1–2 ml endotoxin-free
TE-buffer over night at 4°C. The DNA was re-suspended
and subsequently handled using pipette tips for genomic
DNA (Biozym Art 200 G or 1000 G).BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/2
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Cell culture and transfection
B16F10 (kindly provided by I. J. Fidler, Texas Medical
Center, Houston, TX, USA) murine melanoma cells were
grown in DMEM media 10% FCS, at 37°C with 5% CO2.
Transient transfections were carried out with PEI22 (MBI
Fermentas, St. Leon-Rot, Germany). Cells were seeded in
6-well dishes (5 × 105). 24 hours later, 1 µg (plasmid) or
3 µg (BAC) DNA was diluted in 250 µl HBS buffer (20
mM HEPES, 150 mM NaCl, pH 7.4). Then 0.98 µg PEI22
per 1 µg DNA was diluted in 250 µl HBS. The DNA/PEI so-
lution was mixed by pipetting the solution up and down
approximately 10 times and then incubated for 30 min at
room temp. The old medium was removed from the cells
and 1.5 ml of OPTIMEM added to the cells. The transfec-
tion mix was then added to the cells and left to incubate
for four hours. The medium with the complexes was re-
moved and fresh full growth medium added to the cells.
After overnight incubation the cells were assayed for luci-
ferase or GFP expression.
Stable transfections were carried out with Lipofectamine
2000 (Invitrogen Life Technologies). Cells were seeded in
6-well dishes (2 × 105) the day before transfection. Two µl
of Lipofectamine 2000 was diluted in 250 µl OPTIMEM,
mixed and incubated for 5 min at room temp. 0.5 µg BAC
DNA was diluted in 250 µl OPTIMEM and mixed. The
Lipofectamine 2000/OPTIMEM was added rapidly to the
DNA/OPTIMEM solution and mixed by pipetting up and
down approximately 10 times. The transfection complex-
es were incubated for 30 min at room temp. The old me-
dium was removed from the cells and 1.5 ml of OPTIMEM
added to the cells. The transfection mix was added to the
cells and left to incubate for three hours. The medium
with the complexes was removed and fresh full growth
medium added to the cells. After an overnight incubation,
the cells were trypsinized and 1/16 of the cells seeded
onto each of 4 separate 10-cm tissue culture plates. The
medium was replaced on day 3 with fresh medium con-
taining 800 µg/ml G418. The selective medium was re-
placed on day 6 and 9. On day 10 colonies were picked
into 24 well plates. On day 14 they were transferred into
T25 flasks and from then on passaged twice a week (twice
at 1:5 dilution and thereafter at 1:10). GFP expressing cells
were counted at day 30 and DNA preparations were car-
ried out at day 35.
Luciferase and GFP assays
Luciferase assays were carried out on transiently transfect-
ed cells and on mouse organs. For transiently transfected
cells, the culture medium was removed from the 6-well
dish and the cells were washed once with PBS. The cells in
each well were lysed with 1 ml of lysis buffer (25 mM Tris-
Phosphate pH 7.8, 2 mM DTT, 2 mM CDTA (trans-1,2-di-
aminocyclohexans-N,N,N',N'-tetra-acetic acid), 1% Tri-
ton-X100, 10% glycerol) for 5 minutes and snap frozen in
liquid nitrogen. For mouse muscles, approximately 200
mg from the right upper thigh muscle of treated mice were
dissected 24 hours after electroporation and placed into
600 µl of ice cold 250 mM Tris-HCl pH 7.8. The tissue was
homogenised on ice for one minute using an IKA Ultra-
Turrax homogenizer. Samples were snap frozen in liquid
nitrogen immediately and stored at -80°C.
Samples were rapidly thawed in a waterbath at 37°C and
immediately centrifuged for 10 min at 15,000 rpm and
4°C. For measurement, 350 µl assay buffer (25 mM gly-
cyl-glycin pH 7.8, 15 mM MgSO4, 5 mM ATP) and 10 µl
of cell lysate or 50 µl of supernatant of organ homogenate
were mixed in a Sarstedt (No. 55.476) tube and luciferase
activity was quantified using a LUMAT LB 9507 (Fa.
Berthold, Bad Wildbad, Germany). To do this, 300 µl of
injection buffer (20 mM glycyl-glycine pH 7.8, 0.2 mM so-
dium salt of D-Luciferin (SIGMA)) were added and light
units were measured for 10 seconds.
Luciferase assay background (approximately 50 light
units) was subtracted from each value. One million light
units correspond to approximately 2 ng luciferase. Counts
shown in the figures were calculated as RLU (relative light
units) per transfection sample or RLU per organ in total.
For counting GFP-expressing cells, cells were trypsinized,
fixed with 2% paraformaldehyde in PBS for 45 minutes at
room temperature, washed twice in PBS and counted with
a BD LSR (Beckton Dickinson) FACs using Cell Qest
software.
Rescue of BAC DNA into E. coli
In order to determine whether the oriP/EBNA-1 BACs were
intact in the mammalian cells after 5 weeks culture, high-
molecular-weight DNA was prepared from the cell lines
and electroporated into bacteria.
To prepare high-molecular-weight DNA, cells were har-
vested by trypsinisation, suspended in full media, washed
twice with PBS and suspended at 4 × 107 cells per ml in
PBS. The cell suspension was warmed to 42°C and mixed
with 1 volume of 1.5% low-melting agarose (Sigma) in
0.125 M EDTA pH 8.0 equilibrated to 42°C. The mixture
was then aliquotted into 75-µl plugmolds (BioRad) and
left for 5 minutes on ice. The plugs were then transferred
into a 1.5 ml tube with 500 µl of NDS solution (1% N-lau-
royl sarcosine, 10 mM Tris-HCl pH 7.8, 0.39 M EDTA, 2
mg/ml proteinase K added freshly) and incubated for 1
hour at 55°C. The NDS solution was removed and the
plugs were washed three times with EDTA mix (50 mM
EDTA, 10 mM Tris-HCl pH 7.5) at room temperature for
30 min each wash. They were then washed twice with 1 ×
agarase buffer (NEB) on ice for 30 min each wash.BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/2
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For electroporation into E. coli, a plug was melted at 65°C
for 10–15 min, cooled to 45°C for 5–10 min and 1 µl
agarase (NEB) added per plug. The plugs were incubated
for 1 hour at 42°C and diluted with 1 volume of sterile
water. Two µl of the DNA solution was electroporated
into 40 µl DH10B ElectroMax bacteria (Invitrogen Life
Technologies) using a BioRad GenePulser with 0.1 cm cu-
vettes and 2.5 kV, 25 µF, and 100 Ohm. 1 ml of SOC me-
dium (Gibco) was added and the bacteria incubated with
shaking at 37°C for 1 hour. Bacteria were plated out onto
LB with chloramphenical at 12.5 µg/ml.
Conventional agarose gels and pulsed-field gels
Conventional agarose gels were carried out using 0.3%
SeaKem Gold Agarose (Biozym) in 1 × TAE. Gels were run
in 1 × TAE at a constant voltage of 80 V for two to three
hours in standard horizontal agarose electrophoresis cells
(Biorad).
Pulsed-field gels were carried out using ultraPURE agarose
(Gibco) at 1% in 0.5 × TBE. Gels were run in 0.5 × TBE at
14°C for 18 hours over night, with a fixed angle of 120°,
switching times from 5 sec to 1 sec and 5.9 V/cm using a
Chef-DRIII and a Mini Chiller model 1000 with a variable
speed pump (BioRad).
Gels were stained with ethidium bromide and the DNA
was visualised with UV light.
In vivo electroporation
BALB/c mice were anaesthesised and the right leg was
shaved. 20 µg of plasmid or BAC DNA was diluted in 50
µl of 150 mM NaCl and injected into the right upper thigh
muscle. The muscle was immediately electroporated with
a two needle electrode device (5 mm distance between
electrodes; Genetronics, San Diego) placed on either side
of the injection site. Three pulses of 90 V for 25 ms and
then three more pulses of 90 V for 25 ms in the opposite
orientation were applied with a square wave pulse gener-
ator (BTX, San Diego). Three animals were electroporated
for each type of DNA and the error bars show standard de-
viations. All mice work was carried out according to local
ethical committee guidance.
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